Capital for Reprogen
- Share via
Outside investors continue to scout around Orange County’s biotech industry, looking for pay dirt.
Consider Reprogen Inc., an Irvine developer of gene-based therapies for treating reproductive diseases. The company, which employees 15 people, recently raised $6.5 million from venture capitalists from places as far away as Canada, Germany and Belgium.
Funds will support the company’s attempt to define gene targets for new drugs to combat diseases of the breast, uterus, ovaries and prostate.
*
Barbara Marsh covers health care for The Times. She can be reached at (714) 966-7762 and at [email protected]
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
